

RESEARCH ARTICLE

Open Access

# Genetic network identifies novel pathways contributing to atherosclerosis susceptibility in the innominate artery

Jody Albright<sup>3</sup>, Pamela M Quizon<sup>3</sup>, Aldons J Lusis<sup>4,5,6</sup> and Brian J Bennett<sup>1,2,3\*</sup>

## Abstract

**Background:** Atherosclerosis, the underlying cause of cardiovascular disease, results from both genetic and environmental factors.

**Methods:** In the current study we take a systems-based approach using weighted gene co-expression analysis to identify a candidate pathway of genes related to atherosclerosis. Bioinformatic analyses are performed to identify candidate genes and interactions and several novel genes are characterized using *in-vitro* studies.

**Results:** We identify 1 coexpression module associated with innominate artery atherosclerosis that is also enriched for inflammatory and macrophage gene signatures. Using a series of bioinformatics analysis, we further prioritize the genes in this pathway and identify *Cd44* as a critical mediator of the atherosclerosis. We validate our predictions generated by the network analysis using *Cd44* knockout mice.

**Conclusion:** These results indicate that alterations in *Cd44* expression mediate inflammation through a complex transcriptional network involving a number of previously uncharacterized genes.

**Keywords:** Atherosclerosis, Co-expression network, inflammation

## Background

Cardiovascular disease (CVD) is the leading cause of death in the United States and the incidence of CVD is rapidly increasing in other countries [1]. A common cause of cardiovascular disease is atherosclerosis, a pathological process resulting from an inflammatory response to lipids deposited in the artery wall. Atherosclerosis is a highly complex disease involving interactions among numerous genetic and environmental factors [2]. Well established risk factors for atherosclerosis include: gender, race, dyslipidemia, diabetes and a family history of disease; however these factors alone do not account for differences in susceptibility to atherosclerosis. Based on human post-mortem studies as well as experimental studies in model organisms, it appears that these systemic risk factors

act in part by affecting local inflammation in the vessel wall [3-5].

Inflammation is a fundamental biological process that provides protection from infection, but when dysregulated, acts as a source of chronic disease. In particular, there has been considerable interest in the role of inflammation in the etiology of atherosclerosis [6,7] and improving our understanding of how inflammatory pathways affect atherosclerosis may identify new therapeutic targets. Unfortunately, understanding how to regulate the immune system to reduce chronic disease-associated inflammation has been difficult. Monocyte-derived cells, such as macrophages and dendritic cells, are critical to immune system function and are intimately involved in atherosclerosis [8-10]. These cells along with lymphocytes are found at sites of inflammation and within atherosclerotic lesions [11]. Macrophages are of particular interest because macrophage deficiency prevents atherosclerotic lesion formation in mice [12,13] and because macrophage emigration from lesions leads to reduced lesion size [14]. Thus, identification of pathways that regulate vascular

\* Correspondence: bennettb@email.unc.edu

<sup>1</sup>Department of Genetics, University of North Carolina, Chapel Hill, 500 Laureate Way, Suite 2303, Kannapolis, NC 28081, USA

<sup>2</sup>Department of Nutrition, University of North Carolina, Chapel Hill, NC 2808, USA

Full list of author information is available at the end of the article

inflammation and macrophage function may provide novel therapeutic targets.

We previously published Quantitative Trait Locus (QTL) studies that identified a novel locus controlling innominate artery (IA) lesion size, with a 95% confidence interval spanning 14 Mb on Chromosome 2. These studies used F2 progeny from a genetic cross between C57BL/6J. *Apoe*<sup>-/-</sup> mice, classically characterized as atherosclerosis susceptible, and C3H/HeJ. *Apoe*<sup>-/-</sup> mice, classically characterized as atherosclerosis resistant [15]. Surprisingly, this QTL was not identified to regulate atherosclerosis in the aortic sinus of mice from the same cross [16], indicating a unique genetic contribution among various vascular sites. Furthermore, the susceptible allele for this QTL was derived from the C3H/HeJ mice, the strain historically characterized as atherosclerosis resistant [16-18]. Among the 360 genes within the QTL, we identified *Cd44* as a high probability candidate gene for this QTL based on its physical location within the QTL boundary, the high correlation between IA atherosclerosis and the mRNA levels of *Cd44*, and prior reports of its role in atherosclerosis [19,20] and inflammation [21]. However, the gene(s) within the QTL responsible for the increased atherosclerosis susceptibility and more importantly a mechanism for the increased susceptibility remains unknown.

The primary objective of this study was to identify novel pathways and mechanisms contributing to innominate artery atherosclerosis. Using Weighted Gene Co-Expression Network Analysis (WGCNA) we identify a module (group) of highly related transcripts, correlated with IA lesion size. This module is enriched with genes normally expressed in macrophages suggesting either the influence of Kupfer cells in the liver or general alteration of tissue macrophage response to atherosclerotic stimuli. We characterize the expression of several of the genes in this module through cell culture experiments using primary macrophages. Causal modeling using Network Edge Orienting analysis confirm *Cd44* as a likely causal gene within this pathway. We also identify several key genes within the module that are sensitive to altered *Cd44* expression and likely to affect atherosclerosis risk.

## Methods

### Quantitative trait locus studies

QTL results have been previously reported [15]. In brief, C57BL/6J. *Apoe*<sup>-/-</sup> mice were purchased from The Jackson Laboratory and C3H/HeJ. *Apoe*<sup>-/-</sup> mice were bred by backcrossing B6. *Apoe*<sup>-/-</sup> to C3H/HeJ for 10 generations. F2 mice (BxH *Apoe*<sup>-/-</sup>) were generated by crossing B6. *Apoe*<sup>-/-</sup> with C3H. *Apoe*<sup>-/-</sup> and subsequently intercrossing the F1 mice as described [16]. The F2 mice (n = 86) mice were fed a Western diet (Teklad 88137) containing 42% fat and 0.15% cholesterol for 16 weeks until euthanasia and innominate artery phenotyping at 24 weeks

of age. A genetic map with markers about 1.5 cM apart was constructed using SNP markers as described [16]. RNA was isolated from tissues of the F2 mice using Trizol and microarray analysis was performed on the RNA using 60mer oligonucleotide chips (Agilent Technologies) as previously described [22]. Expression data can be obtained from GEO databases for liver (GSE2814).

### Weighted gene co-expression network analysis

Network analysis was performed using the WGCNA R package [23]. An extensive overview of WGCNA, including numerous tutorials, can be found at <http://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/WGCNA/> and this method has been extensively used to create co-expression networks [23-28]. To begin, we filtered the array data to include 8173 probes expressed in the liver as previously described [29]. To generate a co-expression network for the selected probes, an adjacency matrix is created by first calculating the pairwise gene:gene correlations for all 8173 probes and then raising the Pearson correlation to the 8th power. The power was selected using the scale-free topology criterion, which is determined by the function “pickSoftThreshold” in the WGCNA package [23,30]. Network connectivity (k<sub>total</sub>) of the genes was calculated as the sum of the connection strengths with all other network genes. A TOM-based dissimilarity measure was used for hierarchical clustering of the genes. Gene modules corresponded to the branches of the resulting dendrogram and were defined using the “Dynamic Hybrid” branch cutting algorithm [31]. The parameters for module generation were as follows: “cut height” parameter was set to 0.97 and the “minimum module size” parameter was set to 50. Gene significance (GS) for each gene was determined and is defined as the correlation between innominate artery atherosclerosis and expression of probes. Module significance (MS) was calculated as the mean GS for all module genes. Module eigengenes were defined as the first principal component calculated using PCA. Overall network visualization and sub-networks were visualized using Cytoscape [32].

### Gene ontology

We performed a Gene Ontology (GO) enrichment analysis for network modules using the Database for Annotation, Visualization and Integrated Discovery (DAVID) using the functional annotation clustering option [33]. Functional annotation clustering combines single categories with a significant overlap in gene content and then assigns an enrichment score (ES; defined as the  $-\log^{10}$  of the geometric mean of the unadjusted P-values for each single term in the cluster) to each cluster.

### Causality modeling

Causal relationships were identified using Network edge orienting (NEO) as previously described [34]. An R package is available at <http://labs.genetics.ucla.edu/horvath/aten/NEO/> and assigns direction to the edges of a network using structural equation models that integrate genetic markers, gene expression levels and clinical traits. NEO estimates the probability of 3 models: causal, reactive and independent. We restricted the analyses to the peak marker of the Chr 2 QTL for innominate artery atherosclerosis, individual gene expression levels for genes in the brown module, and size of innominate artery atherosclerosis. We used the single marker analysis function of NEO (LEO.NB.SingleMarker) score, which is the log10 probability of this model divided by the log10 probability of the next best fitting alternative model [34]. LEO scores in excess of 0.3 were set as a threshold of for further investigation as a value of 0.3 indicates that the causal model is two times more likely, given the data, than the next best model, similar to previous studies [24,35]. The Root Mean Square Error of Approximation (RMSEA) is an index of model fit and was used to evaluate the overall model fit for NEO. RMSEA indices close to zero indicate good model fit and a threshold of 0.05 was used as previously suggested [34].

### Cell culture studies

C57BL/6J, C3H/HeJ and *Cd44*<sup>-/-</sup> mice were purchased from the Jackson Laboratory and bred at the David Murdock Research Institute. Mice were handled in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health under protocols approved by the Institutional Animal Care and Use Committees of the North Carolina Research Campus (Protocol Number: 12-003). Mouse peritoneal macrophages were isolated from C57BL/6J, C3H/HeJ and *CD44*<sup>-/-</sup> four days after an IP injection of thioglycolate as previously described [36]. Cells were washed with PBS, red blood cells lysed using ACK lysis buffer, and the remaining counted and plated at 100,000 cells per cm<sup>2</sup> into 12 well plates. Cells were grown in DMEM (Hyclone, Logan, Utah) supplemented with 20% FBS (Hyclone, Logan, Utah) overnight, rinsed with PBS and then adherent cells treated in 1% FBS alone as a control or stimulated with LPS (List Biological Inc., Campbell, CA, #201). Cells were treated for 4 hours except for time-course experiments. RNA was extracted using a Maxwell instrument (Promega, Madison WI) and RNA quality was assessed using an Experion Bioanalysis system (BioRad, Hercules CA).

### Real time PCR

Total RNA was isolated according to manufacturer's specifications using Promega's Maxwell 16 with the Maxwell

16 Cell LEV Total RNA Purification Kit (Promega, AS1225). cDNA was synthesized using Applied Biosystems High Capacity cDNA Reverse Transcription Kit (Life Technologies, 4368813). qPCR was done on a Roche Lightcycler 480 II using Kapa SYBR FAST Master Mix (KAPA, KK4609). Relative gene expression was determined using an efficiency corrected method, and efficiency was determined from a 3-log serial dilutions standard curve made from cDNA pooled from all samples. Primers were designed across exon-exon boundaries using Roche UPL guidelines. Results were normalized to *Rpl4*.

### Repository data

Publicly available micro-array data (*GEO10000*), which contained replicate samples of aortas from C57BL/6J mice as well as *Apoe*<sup>-/-</sup> mice at 6 weeks and 36 weeks of age was downloaded from gene expression omnibus. We matched the genes in our network and this dataset by Entrez gene IDs, and assigned probes to the corresponding module. We examined the expression of our candidate genes in human endarterectomy samples using publicly available micro-array data GSE43292. In brief, carotid endarterectomy collected in 32 hypertensive patients. The samples contained media and neo-intima without adventitia. They were paired, including for each patient one sample of the atheroma plaque (stage IV and over of the Stary classification [37]) containing core and shoulders of the plaque, and one sample of distant macroscopically intact tissue (stages I and II).

### Statistical analysis

Statistical analysis was performed using Prism Graphpad software (V5.0). Comparison between control and treatment group(s) was carried out using either a Student's t test or one-way ANOVA, and statistical significance is shown as described in the figure legends.

## Results



### Transcriptional network analysis identifies pathway contributing to atherosclerosis

QTL studies have demonstrated the genetic complexity of atherosclerosis; however, actual identification of the causal gene(s) underlying these QTL is difficult. The difficulty validating candidate genes identified in QTL studies is primarily due to the poor resolution of the approach, large regions of chromosomes are identified and often contain hundreds of genes [38]. For example, the novel locus on Chromosome 2 controlling atherosclerosis development in the IA contains 360 genes [15]. We used global hepatic gene expression, from microarrays, and a network-based approach to further interrogate the effect of this locus. These expression data have previously been used to identify co-expressed genes regulating bodyweight and the metabolic syndrome [39]. Our current study used a subset

of the mice (n = 89) that were phenotyped for innominate artery atherosclerosis, an artery that recapitulates human atherosclerosis [40]. The current study uses a series of analytical analyses and cell culture experiments to further interrogate this locus and an overview of the analyses and experiments is shown in Figure 1.

We constructed a co-expression network by grouping the expression of genes in the liver based on their topologic overlap, using Weighted Gene Co-expression Network Analysis (WGCNA) [23]. To perform the current analysis, we selected 8173 probes representing 8023 unique genes as previously described [22], from the microarray data. We implemented WGCNA with stringent parameters which resulted in 4485 genes being divided into 10 co-expression modules (groups of co-expressed genes) while the remaining 3538 genes were not able to form a module and have not been further analyzed (Additional file 1: Table S1). The hierarchical clustering of the genes into modules is shown in Additional file 2: Figure S1 and the topological overlap of the modules in Additional file 2: Figure S2. The overall network structure was visualized in Cytoscape [32] (Figure 2).

We next performed enrichment analysis using DAVID [33] and found that eight of the 10 modules were



significantly enriched with genes representing specific Gene Ontology (GO or Kyoto Encyclopedia of Genes and Genomes (KEGG) classifications (Table 1). A list of each gene contained in the 10 modules is provided in Additional file 1: Table S1 and all enrichment categories for the modules are provided in Additional file: 3 Table S2.

While the network was based on hepatic gene expression, the Chr 2 locus was not associated with plasma lipid levels [15]; Thus, we hypothesized that our network analysis would identify novel, non-lipid mediated, pathways associated with lesion development. To determine which genes and modules were related to lesion size, we calculated two metrics, the *Gene Significance (GS)* and *Module Significance (MS)*. The GS is the absolute value of the correlation (Pearson's r) between the expression of each gene in our network and the extent of lesion development in the innominate artery [23] and is used to identify genes that are related to lesion size. The MS is the mean GS for each module [23] and is used to identify which modules are most highly correlated with lesion size. To determine the significance threshold for the MS metric we created 10000 sets of 400 GS values and calculated the correlation with IA atherosclerosis. Using a 1-sided distribution of 0.95 we found that a MS of 0.15 corresponds to a  $p < 0.05$ . From this, we identified 3 modules that exceeded this threshold, (brown, red and salmon Figure 3A), and so were significantly related to IA lesion size.


We next hypothesized that our atherosclerosis-related network modules should contain genes that are over-represented in atherosclerotic tissue. To perform this analysis we used publically available microarray data (*GEO10000*), which contained replicate samples of aortas from C57BL/6J mice as well as *Apoe*<sup>-/-</sup> mice at 6 weeks

and 36 weeks of age. We matched the genes in our network and this dataset by Entrez gene IDs, and assigned probes to the corresponding module. Of the 4485 genes in our network, this array contains 3992 genes, represented by 8205 probes. These probes were assigned to the corresponding network modules and the fold change in expression was calculated by subtracting the mean log<sub>2</sub> expression values of the C57BL/6 J mice from mean log<sub>2</sub> expression values of the *Apoe*<sup>-/-</sup> mice. At 6 weeks of age, when lesion size was expected to be small, there was no enrichment of any of module (Figure 3B). We repeated this analysis at 36 weeks of age, a time when IA lesion size was developed in the *Apoe*<sup>-/-</sup> mice, and found that only 1 module, (the brown module), contained significant enrichment of genes overexpressed in atherosclerotic tissues (Figure 3C). The co-expression pattern of the Brown Module genes discussed in detail in the current manuscript are shown in Figure 2D.

We again used DAVID [33], to search for tissues and cell types in which these genes were over-represented and found that the brown module is enriched for genes expressed in activated spleen and macrophages ( $p < 8.01 \times 10^{-10}$  and  $p < 2 \times 10^{-06}$ , Bonferroni corrected) Table 1. We confirmed the macrophage specificity of this module by examining the enrichment of the core macrophage signal recently identified by the Immunological Genome (ImmGen) Project [41]. Of the 39 genes comprising the core macrophage transcriptional profile, 26 were assayed in our microarray studies and 13 were enriched in the brown module ( $p < 3.3 \times 10^{-11}$ , Fisher's exact test). The enrichment of other modules was calculated using DAVID and is shown in Additional file 3: Table S2.

**Table 1 Characterization of modules**

Module number	Module	Number of probes	Number of unique genes	Enrichment term	Fold enrichment	FDR
1	Black	726	711	IPR001909:Krueppel-associated box	3.97	$1.39 \times 10^{-07}$
2	Blue	862	847	IPR017973:Cytochrome P450, C-terminal region	4.9	$3.93 \times 10^{-04}$
3	Brown	666	655	GO:0001817 ~ regulation of cytokine production	4.41	$1.64 \times 10^{-08}$
4	Green- yellow	96	94	SP_PIR_KEYWORDS: protein transport	5.45	$4.15 \times 10^{-04}$
5	Magenta	134	132	SP_PIR_KEYWORDS: protein transport	5.45	$4.15 \times 10^{-04}$
6	Pink	173	167	SP_PIR_KEYWORDS: methyltransferase	6.32	0.044
7	Purple	115	111	GO:0030529 ~ ribonucleoprotein complex	5.29	0.012
8	Red	315	315	none		
9	Salmon	524	517	GO:0005578 ~ proteinaceous extracellular matrix	3.1	$2.32 \times 10^{-06}$
10	Turquoise	946	936	GO:0007186 ~ G-protein coupled receptor protein signaling pathway	2.3	$8.39 \times 10^{-10}$
No module	Grey	3616	3538			



**Figure 3 Co-expression Network analysis identifies the Brown module as related to Atherosclerosis. (A).** Mean MS score for each of the 11 network modules. **(B)** Mean module gene expression in atherosclerotic aorta tissue relative to non-atherosclerotic tissue at 6 weeks. **(C)** Mean module gene expression in atherosclerotic aorta tissue relative to non-atherosclerotic tissue at 36 weeks. In panels **(B–C)** expression is presented as the mean log<sub>2</sub> expression for each gene in a module in aorta from C57BL/6 J *Apoe*<sup>-/-</sup> mice minus log<sub>2</sub> expression from wild type C57BL/6 J mice. **(D)** A sub-network of co-expressed genes in the Brown Module including *Cd44* and the brown module hub genes. Gene connectivity determines size of each node. Distance between nodes is determined by the topological overlap. \* denotes significant differences ( $p < 0.05$ ).

### Candidate gene identification in the brown module

We next focused on identifying candidate genes in the brown module that regulate the response to atherosclerotic and inflammatory stimuli. Among the 655 genes in this module, several criteria were used to identify candidate genes. Our first criterion was to prioritize genes by their connectivity because highly connected genes, also called hub genes, have been previously shown to be key regulators of the module [29,42,43]. In particular, connectivity and GS are significantly correlated in the brown module (Additional file 2: Figure S3), further indicating that identifying highly connected genes will yield candidates with a strong relationship to atherosclerosis. The most connected genes in this module are: *Nckap11*, *Evl*, *Apbb1ip*, *Fermt3*, *Ncf2*, *Trpv2*, *Gpsm3*, *Was*, *Plcg2* (Table 2). Our

positional candidate, *Cd44*, was not a highly connected gene ranking 362 out of the 666 genes in the module (Additional file 1: Table S1).

### Hub Gene Expression altered by inflammatory stimulus

Atherosclerotic lesions contain many cell types and the over-representation of the brown module genes in macrophages and activated spleen prompted us to attempt to characterize the brown module genes using *in vitro* systems. We first characterized expression of our key brown module genes in thioglycolate-elicited peritoneal macrophages in the basal state and treated with varying amount of *bacterial lipopolysaccharide (LPS)*. We used *Tnf* expression as a positive control for these experiments to demonstrate induction of an inflammatory response.

**Table 2 Hub Genes in brown module**

Gene symbol	Gene name	Chr	Mb	Kme	Expression regulated byChr 2: eQTL	Role in atherosclerosis	Role in monocyte derived cells	Known candidate for human disease	Leo score	RMSEA
<b>Nckap1l (Hem-1)</b>	NCK associated protein 1 like	15	103	1	Yes (6.18) 105.89 Mb	None Known	Yes [44]	None Known	-1.22	0.255
<b>Evl</b>	Ena-vasodilator stimulated phosphoprotein	12	108	0.93	Yes (6.17) 84.17 Mb	None Known	None	leukocyte adhesion deficiency	-1.46	0.280
<b>Apbb1ip (RIAM)</b>	amyloid beta (A4) precursor protein-binding, family	2	23	0.92	Yes (7.86) 81.80 Mb	None Known	Yes phagocytosis [45]	None Known	-21.27	0.255
<b>Fermt3</b>	fermitin family homolog 3	19	7	0.88	Yes (7.73) 105.89 Mb	None Known	Yes [46]	leukocyte adhesion deficiency	-0.49	0.223
<b>Ncf2</b>	neutrophil cytosolic factor 2	1	153	0.85	Yes (4.23) 84.17 Mb	None Known	Yes [47]	Chronic granulomatous disease	-1.87	0.283
<b>Trpv2</b>	transient receptor potential cation channel, subfamily V, member 2	11	63	0.83	Yes (8.19) 148.90 Mb	None Known	Yes-cell death in response to oxidized LDL [48,49]	None Known	-1.38	0.275
<b>Gpsm3</b>	G-protein signaling modulator 3	17	34	0.82	Yes (5.81) 105.89 Mb	None Known	Yes [50]	None Known	-1.76	0.28
<b>Was</b>	Wiskott-Aldrich syndrome homolog	X	8	0.81	none		Yes [51]	Wiskott-Aldrich syndrome	-1.33	0.268
<b>Plcg2</b>	phospholipase C, gamma 2	8	117	0.80	Yes (7.38) 105.89 Mb	None Known	Yes [52,53]	Familial cold autoinflammatory syndrome	-0.98	0.254
<b>Cd44</b>	CD44 antigen	2	102	0.26	Yes	Yes	Yes	None Known	1.01	0.000

Kme- is the weighted connectivity for the gene. LEO.NB, log10 ratio of causal model to all other model probabilities;  $-\log_{10}P$ , RMSEA, a model fit index (index close to 0 indicates good fit of the causal model).

We repeated these experiments with doses of *LPS* between 2 and 200 ng/ml. We observed significant induction of *Apbb1ip*, and *Cd44* while *Evl*, *Fermt3*, *Gpsm3* and *Was* were down-regulated by increasing amounts of *LPS* (Additional file 2: Figure S4). We also examined the time course response for the brown module genes for treatment times ranging from 2 to 8 hours, and observed that these genes are responsive to *LPS* in a time-dependent manner (Additional file 2: Figure S5). These experiments were also conducted in RAW 264.7 cells with similar results (data not shown).

#### Hub gene expression varies by strain

The original QTL was found in a cross between C57BL/6 J and C3H/HeJ mice. We therefore next sought to determine expression level of our key candidate genes in peritoneal macrophages from both of these strains with and without the addition of 10 ng/ml *LPS*. We found that *Apbb1ip*, *Cd44*, *Evl*, *Fermt3*, *Gpsm3*, *Ncf2*, *Nckap1l*, *Plcg2*, *Trpv2*, and *Was* were differentially expressed between strains in unstimulated cells (Figure 4). As expected there was no response in C3H/HeJ to *LPS* as these mice are defective in *Thr4* signaling (Figure 4).

#### Characterizing transcriptional regulation of the brown module

Our WGCNA analysis groups the genes by topological overlap and develops an undirected network with a module (Brown module) of highly connected genes that is associated with innominate artery atherosclerosis. We previously reported an expression QTL (eQTL) for *Cd44* [41] and hypothesized that additional genes in the brown module may be regulated by the Chr 2 locus *in trans* (distant eQTL). Several of our hub genes *Nckap1l*, *Fermt3*, *Trpv2*, *Gpsm3* and *Evl*, have eQTL that map to the Chr 2 locus (distant eQTL) Table 2 and <http://systems.genetics.ucla.edu/data> [54]. The existence of several distant eQTL indicates that a common genetic variant at Chr 2 is regulating the expression of these genes. However, we have not assessed the relationship among the genes in the Brown module nor how transcriptional changes to specific transcripts may alter expression of the Brown module.

To better assess relationship between individual genes in the Brown module and atherosclerosis, we utilized Network Edge Orienting (NEO), a freely available R package [34], to assess the causal relationships between the peak SNP associated with IA lesion size, rs368994, the hepatic expression of genes contained in the Brown module and IA atherosclerosis. This analysis showed that *Cd44* had the highest LEO score indicating that it is the brown module gene with the highest likelihood of a causal relationship with atherosclerosis (Table 2). No other genes in the Brown module had a significant LEO score indicating that differences in *Cd44* expression are

proximal to atherosclerosis as compared to the remaining Brown module Genes. Thus, we hypothesized that perturbations in *Cd44* expression may affect the gene expression of genes within the Brown module.


To investigate the role of *Cd44* on the expression of these module genes, we isolated thioglycolate-elicited peritoneal macrophages from *Cd44*<sup>-/-</sup> and wild-type mice, on a C57BL/6J mice genetic background, and performed qPCR. We first compared the expression of the Brown module genes in unstimulated macrophages and observed small but statistically significant differences in *Fermt3*, *Gpsm3*, *Nckap1l*, and *Plcg2*. We also determined the response to *LPS* in both *Cd44*<sup>-/-</sup> and WT macrophages and observed significant differences in *Cd44*, *Fermt3*, *Trpv2* and *Was* in response to *LPS* (Figure 5). These results indicate that *Cd44* expression is upstream of the Brown module hub genes and is altering expression of these genes.

We next sought to use NEO to identify which of the module genes are directly downstream of *Cd44*. Thus, we repeated our NEO analysis with hepatic *Cd44* expression as the trait of interest. We used a LEO score of 0.3 as a threshold and predicted that 233 in the brown module genes are downstream of *Cd44*. Interestingly, of the 9 Hub genes, only *Fermt3*, *Trpv2* and *Plcg2* were predicted to be directly downstream of *Cd44*, indicating the effects of *Cd44* on the remaining 3 hub genes that are differentially expressed in *Cd44*<sup>-/-</sup> macrophages are mediated by additional module members. In an attempt to further characterize the Brown module genes that may be responding to alterations in *Cd44*, we focused on validating the 9 additional genes with the highest LEO score (Table 3). To do so we first performed qPCR for the key module genes on thioglycolate-elicited peritoneal macrophages from *Cd44*<sup>-/-</sup> and *Cd44*<sup>+/+</sup> mice. We compared the expression of the brown module genes in unstimulated macrophages and observed small but statistically significant differences in *Kcng2*, *Dapp1*, *Neur12*, *Fmnl2*, *Calhm2*, *Ehd4*, and *Pltp*, between *Cd44* and WT macrophages (Figure 6).

#### Network genes are differentially expressed in human atherosclerotic lesions

To better understand the overall translation of module to human atherosclerosis, we next sought to determine the expression of the module hub genes in human atherosclerotic tissue. We queried the Gene Expression Omnibus and identified GSE43292, a dataset where 32 hypertensive patients were treated for carotid atherosclerosis by endarterectomy. The tissue from the patients was excised and advanced atherosclerotic tissue was compared to adjacent tissue without macroscopic evidence of atherosclerosis and both biopsies were subjected to expression array analysis. In this case all of our identified hub genes were






differentially expressed between lesion and adjacent, normal tissue (Figure 7). There was no significant difference in *Cd44* expression between the macroscopically intact tissue and atherosclerotic tissue.

## Discussion

In the present study we use a network-based approach to interrogate the atherosclerosis susceptibility of the innominate artery. We identify 1 module that is highly related to IA atherosclerosis using liver tissue from a BxH *Apoe*<sup>-/-</sup> genetic intercross in which we identified a major locus for IA atherosclerosis. This module is highly enriched for immune-related genes, in particular those of the monocyte/macrophage lineage. Overall, these studies have resulted in four main findings. First, we confirm that genes in this module are overexpressed in atherosclerotic tissue using publically available microarray data. Second, we demonstrate that the most connected


genes in the module, “hub genes”, are differentially expressed in macrophages stimulated with LPS and between macrophages derived from C57BL/6J and C3H/HeJ mouse strains. Third, using structural equation modeling we predict that *Cd44* as the most likely candidate gene for our previously reported QTL and identify several genes predicted to be downstream of *Cd44*. Lastly, we validate novel interactions among the module genes using macrophages isolated from *Cd44*<sup>-/-</sup> mice. Each of these findings is discussed below.

Our network analysis identified a module that was highly related to atherosclerosis in the IA and this module was highly enriched for genes in activated macrophages and spleen. Using freely available data at NCBI’s Gene Omnibus, we were able to confirm that the genes located in the brown module are significantly upregulated in the aorta of *Apoe*<sup>-/-</sup> mice compared to age matched C57BL/6J mice. These results demonstrate that genetic



**Table 3 Genes predicted responsive to *Cd44***

Gene symbol	Gene name	Chr	Mb	Leo score	% change <i>Cd44</i> <sup>-/-</sup> basal (P-value)
<b>Kcng2</b>	Potassium voltage-gated channel, subfamily G, member 2	18	80	3.1	<b>NS</b>
<b>Dapp1</b>	Dual adaptor for phosphotyrosine and 3-phosphoinositides 1	3	137	3.08	<b>10% (0.05)</b>
<b>Neurl2</b>	Neuralized-like 2 (Drosophila)	2	164	2.99	<b>30% (0.005)</b>
<b>Fmnl2</b>	Formin-like 2	2	52	2.96	<b>17% (0.002)</b>
<b>Calhm2</b>	Calcium homeostasis modulator 2	19	47	2.7	<b>12% (0.03)</b>
<b>Ehd4</b>	EH-domain containing 4	2	120	2.67	<b>10% (0.008)</b>
<b>Pltp</b>	Phospholipid transfer protein	2	164	2.61	<b>18% (0.003)</b>
<b>Tex14</b>	Testis expressed gene 14	11	87	2.52	<b>-30% (0.02)</b>
<b>Vsig4</b>	V-set and immunoglobulin domain containing 4	X	96	2.5	<b>20% (0.03)</b>




networks identified in peripheral tissues, such as the liver, are able to identify biologically meaningful signals with relevance to disease.

None of the hub genes identified in the brown module have been previously linked to atherosclerosis. However, several of them are known to be involved in inflammation. For example, *Nckap1l*, also known as Hem1, was recently found to be an actin regulatory protein that interacts with *Was*, another of the hub genes in the brown module. *Was* has previously been shown to underlie Wiskott-Aldrich syndrome which is characterized by defective clotting and immune function and although *Was* has not been previously identified as a candidate gene for atherosclerosis, altered clotting function and immune function are thought to contribute to atherosclerotic lesion development. *Ncf2* is a causal gene for chronic granulomatous disease, while

mutations in *Fermt3* lead to leukocyte adhesion deficiency, type 3. These data, along with reports of altered immune function in *Cd44*<sup>-/-</sup> mice [21], indicate that interactions among these genes may affect atherosclerosis susceptibility and that this genetic pathway involves alterations in immune function.

In order to better understand how these genes respond to atherosclerosis related inflammatory signals, we stimulated peritoneal macrophages with LPS. These results indicated that the expression of several of these genes is significantly altered upon LPS stimulation. Furthermore, the expression of these differed between the strains of the original cross (C3H/HeJ and C57BL/6J). Together these results support our predicted genetic network. One potential difference between the original QTL study and the current network analysis and transcriptional validation



study is a difference in the hyperlipidemic background of the mice. The original QTL was identified in hyperlipidemic *Apoe*<sup>-/-</sup> mice which were originally developed to elevate lipids and sensitize them to atherosclerosis development [55] and several groups have used mice carrying this sensitizing mutation to identify QTL in mice [16,18,56,57]. We decided to use C3H/HeJ and C57BL/6J mice without the *Apoe*<sup>-/-</sup> mutation based on the fact that the Chr 2 locus was independent of genetic signals for plasma lipids.

Our co-expression network is undirected and thus we cannot easily differentiate between causal and reactive genes for atherosclerosis in the brown module. Considering the known QTL for IA atherosclerosis on Chr 2 [15], we focused on genes which were located within the QTL boundary, and also present in the brown module. Only 11 genes of the Brown module genes are located within the 95% CI of the IA lesion size QTL (Additional file 3: Table S3). Our initial candidate gene highlighted in our previous publication was *Cd44* but we were unable to rule out the other 11 genes which reside in the QTL boundary, nor could we use the differential expression analysis to identify a single gene as 5 of the 11 genes located at the Chr 2 QTL and in the Brown module are

differentially expressed in atherosclerotic tissue (*Cd44*, *Pamr1*, *Nusap1*, *Mertk*, and *Ehd4*).

Thus, we sought to use a bioinformatics approach called network edge orienting, which incorporates genotype data and structural equation modeling to determine causal genes within a gene list. The underlying approach has been validated for lipids and bone mineral density [24,35,43]. For this analysis we used all 666 brown module genes and found that only 1 gene, *Cd44*, was predicted to drive susceptibility to atherosclerosis. Therefore, we focused several experiments on understanding how *Cd44* may regulate expression of genes within brown module. To identify potential novel targets of *Cd44* within the brown module we used two approaches. First we identified which of the hub genes had an eQTL mapping to the atherosclerosis locus on Chr 2. The second approach repeated our NEO analysis using *Cd44* transcript levels as our phenotype of interest and the peak SNP for the atherosclerosis QTL, rs3671635, to anchor the analysis. Using these approaches we identified genes that are likely to be downstream of *Cd44*. To confirm these relationships we used peritoneal macrophages from *Cd44*<sup>-/-</sup> mice and determined that expression of our predicted genes is indeed, modulated in part by *Cd44*. Thus, all of our genes

with eQTL mapping to the atherosclerosis QTL interval *in trans*, *Nckap1l*, *Fermt3*, *Trpv2*, *Gpsm3* and *Evl*, were differentially expressed in *Cd44*<sup>-/-</sup> mice. In addition to these genetic candidates, our NEO analysis identified over 100 genes in the module that are predicted to respond to *Cd44*. We tested 9 of these and confirmed that 8 of these are in fact reactive to *Cd44* expression levels.

Finally, we demonstrated that the brown module hub genes highlighted in this report are differentially expressed in human atherosclerotic tissue suggesting that the module of genes originally identified in the livers of atherosclerotic mice through gene co-expression analysis may, in fact, have a direct role in the development and progression of atherosclerosis. Interestingly, *CD44* was highly expressed in both the atherosclerotic and macroscopically intact adjacent tissue from humans and could indicate an important difference in the regulation of atherosclerosis in humans and mice. Alternatively, the lack of differential expression in the human tissues may reflect a high level of local vascular inflammation in the macroscopically intact tissues. This interpretation is supported by studies that indicate that *Cd44* is an early mediator of atherosclerosis [58] and is upregulated by pro-atherosclerotic cytokines [59]. Additional studies are needed to clarify the role of *CD44* in atherosclerosis and differences between humans and mice in *CD44*'s role in regulating in the inflammatory response.

## Conclusion

We were able to identify 1 module of co-expressed genes that are related to atherosclerosis. This module contains our putative candidate gene and through a series of bioinformatics approaches we identify a potential mechanism for this QTL, through altered macrophage gene expression. None of these candidates has been previously identified as involved in atherosclerosis and thus represent novel targets for further investigation. Together these data demonstrate the utility of a network approach to prioritize genetic candidates and to identify potential mechanisms for candidate genes identified in QTL studies.

## Additional files

**Additional file 1: Table S1.** Module assignments for all network probes. This file contains the module assignments and annotations for each of the microarray probes contained in the bone co-expression network. Columns A–D provide probe annotations. Column E contains the connectivity score for each probe and column F is the module assignments.

**Additional file 2: Figure S1.** Network dendrogram (top) and colors of modules (bottom). **Figure S2.** Topological overlap. Clustering with the topological overlap dissimilarity measure was used to identify gene coexpression modules, each of which was assigned a unique color.

**Figure S3.** Connectivity is correlated with Gene Significance in brown module. **Figure S4.** Inflammatory response of Key Network Genes.

**Figure S5.** Timecourse response to inflammation in Key Network Genes.

**Additional file 3: Table S2.** An excel document with 3 tabs for enrichment analysis. Significant (FDR, 0.05) gene ontology enrichments for all 10 modules. This file is the output from DAVID and contains (FDR 0.05). More information about the output can be found at (<http://david.abcc.ncifcrf.gov/>).

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

JA carried out the molecular *in vitro* experiments and assisted drafting the manuscript. PQ assisted with the *in vivo* studies and assisted drafting the manuscript. AJL participated in the design of the study and assisted drafting the manuscript. BJB conceived of the study, and participated in its design, performed the statistical analysis and drafted the manuscript. All authors read and approved the final manuscript.

## Acknowledgements

This research was supported in part by PO1 HL30568 NIH/NHLBI and PO1 HL28481 NIH/NHLBI (AJL), and K99/R00 HL102223 (BJB).

## Author details

<sup>1</sup>Department of Genetics, University of North Carolina, Chapel Hill, 500 Laureate Way, Suite 2303, Kannapolis, NC 28081, USA. <sup>2</sup>Department of Nutrition, University of North Carolina, Chapel Hill, NC 2808, USA. <sup>3</sup>Nutrition Research Institute, University of North Carolina, Chapel Hill, NC 2808, USA. <sup>4</sup>Department of Medicine, David Geffen School of Medicine of UCLA, Los Angeles, CA 90095, USA. <sup>5</sup>Department of Human Genetics, David Geffen School of Medicine of UCLA, Los Angeles, CA 90095, USA. <sup>6</sup>Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine of UCLA, Los Angeles, CA 90095, USA.

Received: 8 April 2014 Accepted: 17 July 2014

Published: 12 August 2014

## References

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman M, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, et al: **Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association.** *Circulation* 2013, **127**:143–152.
2. Lusis AJ, Mar R, Pajukanta P: **Genetics of atherosclerosis.** *Annu Rev Genomics Hum Genet* 2004, **5**:189–218.
3. Homma S, Ishii T, Malcom GT, Zieske AW, Strong JP, Tsugane S, Hirose N: **Histopathological modifications of early atherosclerotic lesions by risk factors—findings in PDAY subjects.** *Atherosclerosis* 2001, **156**:389–399.
4. Yan ZQ, Hansson GK: **Innate immunity, macrophage activation, and atherosclerosis.** *Immunol Rev* 2007, **219**:187–203.
5. Kolodgie FD, Narula J, Burke AP, Haider N, Farb A, Hui-Liang Y, Smialek J, Virmani R: **Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death.** *Am J Pathol* 2000, **157**:1259–1268.
6. Ross R: **Atherosclerosis—an inflammatory disease.** *N Engl J Med* 1999, **340**:115–126.
7. Libby P: **Inflammation in atherosclerosis.** *Nature* 2002, **420**:868–874.
8. Glass CK, Witztum JL: **Atherosclerosis. the road ahead.** *Cell* 2001, **104**:503–516.
9. Falk E: **Pathogenesis of atherosclerosis.** *J Am Coll Cardiol* 2006, **47**:C7–C12.
10. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: **Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions.** *Arterioscler Thromb Vasc Biol* 2000, **20**:1262–1275.
11. Hansson GK, Libby P: **The immune response in atherosclerosis: a double-edged sword.** *Nat Rev Immunol* 2006, **6**:508–519.
12. Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP, Imes S, Fishbein MC, Clinton SK, Libby P, Lusis AJ, Rajavashisth TB: **Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice.** *Am J Pathol* 1997, **150**:1687–1699.

13. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M: **Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E.** *Proc Natl Acad Sci U S A* 1995, **92**:8264–8268.
14. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA: **Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in Apoe-deficient mice.** *Proc Natl Acad Sci U S A* 2006, **103**:3781–3786.
15. Bennett BJ, Wang SS, Wang XP, Wu X, Lusis AJ: **Genetic regulation of atherosclerotic plaque size and morphology in the innominate artery of hyperlipidemic mice.** *Arterioscler Thromb Vasc Biol* 2009, **29**:348–355.
16. Wang SS, Schadt EE, Wang H, Wang X, Ingram-Drake L, Shi W, Drake TA, Lusis AJ: **Identification of pathways for atherosclerosis in mice: integration of quantitative trait locus analysis and global gene expression data.** *Circ Res* 2007, **101**:e11–e30.
17. Paigen B, Mitchell D, Reue K, Morrow A, Lusis AJ, LeBoeuf RC: **Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice.** *Proc Natl Acad Sci U S A* 1987, **84**:3763–3767.
18. Wang SS, Shi W, Wang X, Velky L, Greenlee S, Wang MT, Drake TA, Lusis AJ: **Mapping, genetic isolation, and characterization of genetic loci that determine resistance to atherosclerosis in C3H mice.** *Arterioscler Thromb Vasc Biol* 2007, **12**:2671–2676.
19. Zhao L, Hall JA, Levenkova N, Lee E, Middleton MK, Zukas AM, Rader DJ, Rux JJ, Pure E: **CD44 regulates vascular gene expression in a proatherogenic environment.** *Arterioscler Thromb Vasc Biol* 2007, **27**:886–892.
20. Zhao L, Lee E, Zukas AM, Middleton MK, Kinder M, Acharya PS, Hall JA, Rader DJ, Pure E: **CD44 expressed on both bone marrow-derived and non-bone marrow-derived cells promotes atherogenesis in Apoe-deficient mice.** *Arterioscler Thromb Vasc Biol* 2008, **28**:1283–1289.
21. Teder P, Vandivier RW, Jiang D, Liang J, Cohn L, Pure E, Henson PM, Noble PW: **Resolution of lung inflammation by CD44.** *Science* 2002, **296**:155–158.
22. Yang X, Schadt EE, Wang S, Wang H, Arnold AP, Ingram-Drake L, Drake TA, Lusis AJ: **Tissue-specific expression and regulation of sexually dimorphic genes in mice.** *Genome Res* 2006, **16**:995–1004.
23. Langfelder P, Horvath S: **WGCNA: an R package for weighted gene co-expression network analysis.** *BMC Bioinform* 2008, **9**:559.
24. Plaisier CL, Horvath S, Huertas-Vazquez A, Cruz-Bautista I, Herrera MF, Tusie-Luna T, Aguilar-Salinas C, Pajukanta P: **A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia.** *PLoS Genet* 2009, **5**:e1000642.
25. Gargalovic PS, Imura M, Zhang B, Gharavi NM, Clark MJ, Pagnon J, Yang WP, He A, Truong A, Patel S, Nelson SF, Horvath S, Berliner JA, Kirchgessner TG, Lusis AJ: **Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids.** *Proc Natl Acad Sci U S A* 2006, **103**:12741–12746.
26. Oldham MC, Horvath S, Geschwind DH: **Conservation and evolution of gene coexpression networks in human and chimpanzee brains.** *Proc Natl Acad Sci U S A* 2006, **103**:17973–17978.
27. van Nas A, Guhathakurta D, Wang SS, Yehya N, Horvath S, Zhang B, Ingram-Drake L, Chaudhuri G, Schadt EE, Drake TA, Arnold AP, Lusis AJ: **Elucidating the role of gonadal hormones in sexually dimorphic gene coexpression networks.** *Endocrinology* 2009, **150**:1235–1249.
28. Park CC, Gale GD, de Jong S, Ghazalpour A, Bennett BJ, Farber CR, Langfelder P, Lin A, Khan AH, Eskin E, Horvath S, Lusis AJ, Ophoff RA, Smith DJ: **Gene networks associated with conditional fear in mice identified using a systems genetics approach.** *BMC Syst Biol* 2011, **5**:43.
29. Yang X, Peterson L, Thieringer R, Deignan JL, Wang X, Zhu J, Wang S, Zhong H, Stepaniants S, Beaulaurier J, Wang JM, Rosa R, Cumiskey AM, Luo JM, Luo Q, Shah K, Xiao J, Nickle D, Plump A, Schadt EE, Lusis AJ, Lum PY: **Identification and validation of genes affecting aortic lesions in mice.** *J Clin Invest* 2010, **120**:2414–2422.
30. Zhang B, Horvath S: **A general framework for weighted gene co-expression network analysis.** *Stat Appl Genet Mol Biol* 2005, **4**:17.
31. Langfelder P, Zhang B, Horvath S: **Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R.** *Bioinformatics* 2008, **24**:719–720.
32. Saito R, Smoot ME, Ono K, Ruschinski J, Wang PL, Lotia S, Pico AR, Bader GD, Ideker T: **A travel guide to Cytoscape plugins.** *Nat Methods* 2012, **9**:1069–1076.
33. da Huang W, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA: **DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists.** *Nucleic Acids Res* 2007, **35**:W169–W175.
34. Aten JE, Fuller TF, Lusis AJ, Horvath S: **Using genetic markers to orient the edges in quantitative trait networks: the NEO software.** *BMC Syst Biol* 2008, **2**:34.
35. Farber CR, van Nas A, Ghazalpour A, Aten JE, Doss S, Sos B, Schadt EE, Ingram-Drake L, Davis RC, Horvath S, Smith DJ, Drake TA, Lusis AJ: **An integrative genetics approach to identify candidate genes regulating BMD: combining linkage, gene expression, and association.** *J Bone Miner Res* 2009, **24**:105–116.
36. Orozco LD, Bennett BJ, Farber CR, Ghazalpour A, Pan C, Che N, Wen P, Qi HX, Mutukulu A, Siemers N, Neuhaus I, Yordanova R, Gargalovic P, Pellegrini M, Kirchgessner T, Lusis AJ: **Unraveling inflammatory responses using systems genetics and gene-environment interactions in macrophages.** *Cell* 2012, **151**:658–670.
37. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW: **A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American heart association.** *Circulation* 1995, **92**:1355–1374.
38. Flint J, Valdar W, Shifman S, Mott R: **Strategies for mapping and cloning quantitative trait genes in rodents.** *Nat Rev Genet* 2005, **6**:271–286.
39. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, Zhang C, Lamb J, Edwards S, Sieberts SK, Leonardson A, Castellini LW, Wang S, Champy MF, Zhang B, Emilsson V, Doss S, Ghazalpour A, Horvath S, Drake TA, Lusis AJ, Schadt EE: **Variations in DNA elucidate molecular networks that cause disease.** *Nature* 2008, **452**:429–435.
40. Rosenfeld ME, Polinsky P, Virmani R, Kausar K, Rubanyi G, Schwartz SM: **Advanced atherosclerotic lesions in the innominate artery of the Apoe knockout mouse.** *Arterioscler Thromb Vasc Biol* 2000, **20**:2587–2592.
41. Gautier EL, Shay T, Miller J, Greter M, Jakubczik C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, Mazloom AR, Ma'ayan A, Chua WJ, Hansen TH, Turley SJ, Merad M, Randolph GJ, Immunological Genome Consortium: **Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages.** *Nat Immunol* 2012, **13**:1118–1128.
42. Yang X, Deignan JL, Qi H, Zhu J, Qian S, Zhong J, Torosyan G, Majid S, Falkard B, Kleinhanz RR, Karlsson J, Castellani LW, Mumick S, Wang K, Xie T, Coon M, Zhang C, Estrada-Smith D, Farber CR, Wang SS, van Nas A, Ghazalpour A, Zhang B, Macneil DJ, Lamb JR, Dipple KM, Reitman ML, Mehrabian M, Lum PY, Schadt EE, et al: **Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks.** *Nat Genet* 2009, **41**:415–423.
43. Calabrese G, Bennett BJ, Orozco L, Kang HM, Eskin E, Dombret C, De Backer O, Lusis AJ, Farber CR: **Systems genetic analysis of osteoblast-lineage cells.** *PLoS Genet* 2012, **8**:e1003150.
44. Park H, Chan MM, Iritani BM: **Hem-1: putting the "WAVE" into actin polymerization during an immune response.** *FEBS Lett* 2010, **584**:4923–4932.
45. Medrano-Fernandez I, Reyes R, Olazabal I, Rodriguez E, Sanchez-Madrid F, Boussiotis VA, Reche PA, Cabanas C, Lafuente EM: **RIAM (Rap1-interacting adaptor molecule) regulates complement-dependent phagocytosis.** *Cell Mol Life Sci CMLS* 2013, **70**:2395–2410.
46. Malinin NL, Zhang L, Choi J, Ciocca A, Razorenova O, Ma YQ, Podrez EA, Tosi M, Lennon DP, Caplan AI, Shurin SB, Plow EF, Byzova TV: **A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans.** *Nat Med* 2009, **15**(3):313–318.
47. Sancho-Shimizu V, Malo D: **Sequencing, expression, and functional analyses support the candidacy of Ncf2 in susceptibility to Salmonella typhimurium infection in wild-derived mice.** *J Immunol* 2006, **176**:6954–6961.
48. Santoni G, Farfariello V, Liberati S, Morelli MB, Nabissi M, Santoni M, Amantini C: **The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses.** *Front Immunol* 2013, **4**:34.
49. Szollosi AG, Olah A, Toth IB, Papp F, Czifra G, Panyi G, Biro T: **Transient receptor potential vanilloid-2 mediates the effects of transient heat shock on endocytosis of human monocyte-derived dendritic cells.** *FEBS Lett* 2013, **587**:1440–1445.

50. Giguere PM, Billard MJ, Laroche G, Buckley BK, Timoshchenko RG, McGinnis MW, Esserman D, Foreman O, Liu P, Siderovski DP, Tarrant TK: **G-protein signaling modulator-3, a gene linked to autoimmune diseases, regulates monocyte function and its deficiency protects from inflammatory arthritis.** *Mol Immunol* 2013, **54**:193–198.
51. Imai K, Nonoyama S, Ochs HD: **WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype.** *Curr Opin Allergy Clin Immunol* 2003, **3**:427–436.
52. Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R: **PLCGamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2.** *J Clin Invest* 2006, **116**:2869–2879.
53. Zhou Q, Lee GS, Brady J, Datta S, Katan M, Sheikh A, Martins MS, Bunney TD, Santich BH, Moir S, Kuhns DB, Long Priel DA, Ombrello A, Stone D, Ombrello MJ, Khan J, Milner JD, Kastner DL, Aksentijevich I: **A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.** *Am J Hum Genet* 2012, **91**:713–720.
54. van Nas A, Pan C, Ingram-Drake LA, Ghazalpour A, Drake TA, Sobel EM, Papp JC, Luskis AJ: **The systems genetics resource: a web application to mine global data for complex disease traits.** *Front Genet* 2013, **4**:84.
55. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: **Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.** *Cell* 1992, **71**:343–353.
56. Dansky HM, Shu P, Donovan M, Montagno J, Nagle DL, Smutko JS, Roy N, Whiteing S, Barrios J, McBride TJ, Smith JD, Duyk G, Breslow JL, Moore KJ: **A phenotype-sensitizing Apoe-deficient genetic background reveals novel atherosclerosis predisposition loci in the mouse.** *Genetics* 2002, **160**:1599–1608.
57. Smith JD, Bhasin JM, Baglione J, Settle M, Xu Y, Barnard J: **Atherosclerosis susceptibility loci identified from a strain intercross of apolipoprotein E-deficient mice via a high-density genome scan.** *Arterioscler Thromb Vasc Biol* 2006, **26**:597–603.
58. Zhao L, Hall JA, Levenkova N, Lee E, Middleton MK, Zukas AM, Rader DJ, Rux JJ, Pure E: **CD44 regulates vascular gene expression in a proatherogenic environment.** *Arterioscler Thromb Vasc Biol* 2007, **27**:886–892.
59. Raines EW, Ferri N: **Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease.** *J Lipid Res* 2005, **46**:1081–1092.

doi:10.1186/1755-8794-7-51

**Cite this article as:** Albright *et al.*: Genetic network identifies novel pathways contributing to atherosclerosis susceptibility in the innominate artery. *BMC Medical Genomics* 2014 **7**:51.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

